Pulmonary systemic sclerosis

This study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…

This phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…

This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…

This study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…

This study looks at whether artificial intelligence can analyze CT scans of the lungs to predict how systemic sclerosis (a rare autoimmune disease) will affect the lungs over time. Researchers will review past scans and health records of 1,000 patients to see if certain imaging f…